Thijs H Oude Munnink (Thijs Oude Munnink)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Metastatic Breast Cancer

Top Venues

Clinical pharmacokinetics

JCO precision oncology

European journal of cancer care

This page only lists publications with an associated author ORCID identifier.

Publications

Thijs H Oude Munnink, Saskia K Klein, Daan J Touw
Comment on: "CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients". Clinical pharmacokinetics 63 (6) (2024)
André B P van Kuilenburg, Marjolein C H Pleunis-van Empel, Rick B Brouwer, Angelique E J Sijben, Daan G Knapen, Thijs H Oude Munnink, Jelmer J van Zanden, Jenny Janssens-Puister, Doreen Dobritzsch, Rutger Meinsma, Judith Meijer-Jansen, Silvy J M van Dooren, Raymon Vijzelaar, Ana Pop, Gajja S Salomons, Jan Gerard Maring, Klary E Niezen-Koning
Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants. JCO precision oncology 8 (2024)
Thijs H Oude Munnink, Saskia K Klein, Daan J Touw
Comment on: "CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients". Clinical pharmacokinetics 63 (6) (2024)
Fieke M Rosenberg, Zoha Kamali, Angelique N Voorberg, Thijs H Oude Munnink, Peter J van der Most, Harold Snieder, Ahmad Vaez, Marie-Louise A Schuttelaar
Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema. Pharmaceutics 16 (4) (2024)
Fieke M Rosenberg, Zoha Kamali, Angelique N Voorberg, Thijs H Oude Munnink, Peter J van der Most, Harold Snieder, Ahmad Vaez, Marie-Louise A Schuttelaar
Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema. Pharmaceutics 16 (4) (2024)
André B P van Kuilenburg, Marjolein C H Pleunis-van Empel, Rick B Brouwer, Angelique E J Sijben, Daan G Knapen, Thijs H Oude Munnink, Jelmer J van Zanden, Jenny Janssens-Puister, Doreen Dobritzsch, Rutger Meinsma, Judith Meijer-Jansen, Silvy J M van Dooren, Raymon Vijzelaar, Ana Pop, Gajja S Salomons, Jan Gerard Maring, Klary E Niezen-Koning
Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants. JCO precision oncology 8 (2024)
Dirk Jan A R Moes, Jeroen J M A Hendrikx, Henk-Jan Guchelaar, Ron H J Mathijssen, J L Bakker, Vincent O Dezentjé, Nikki de Rouw, Nielka P van Erp, Egbert F Smit, Michel van den Heuvel, Thijs H Oude Munnink, Maartje van Kats, Sander Croes, Judith R Kroep, Juliette Zwaveling, Rob Ter Heine
Model-Informed Development of a Cost-Saving Dosing Regimen for Sacituzumab Govitecan. Targeted oncology (2024)
Thijs H Oude Munnink, Saskia K Klein, Daan J Touw
Comment on: "CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients". Clinical pharmacokinetics (2024)
Niels Westra, Daniel J Touw, Marjolijn N Lub-de Hooge, Jos Kosterink, Thijs H Oude Munnink
Pharmacokinetic Boosting of Kinase Inhibitors. Pharmaceutics 15 (4) (2023)
Niels Westra, Daniel J Touw, Marjolijn N Lub-de Hooge, Jos Kosterink, Thijs H Oude Munnink
Pharmacokinetic Boosting of Kinase Inhibitors. Pharmaceutics 15 (4) (2023)
Niels Westra, Daniel J Touw, Marjolijn N Lub-de Hooge, Jos Kosterink, Thijs H Oude Munnink
Pharmacokinetic Boosting of Kinase Inhibitors. Pharmaceutics 15 (4) (2023)
Niels Westra, Daniel J Touw, Marjolijn N Lub-de Hooge, Jos Kosterink, Thijs H Oude Munnink
Pharmacokinetic Boosting of Kinase Inhibitors. Pharmaceutics 15 (4) (2023)
Elze Vrijkorte, Jennifer de Vries, Ron Schaafsma, Machteld Wymenga, Thijs H Oude Munnink
Optimising pharmacotherapy in older cancer patients with polypharmacy. European journal of cancer care 29 (1) (2019)